Regeneron Pharmaceuticals has entered a strategic collaboration with TriNetX to connect its large-scale genomic and proteomic data with TriNetX's extensive global electronic health record (EHR) network of 300 million anonymized patients. This partnership will expand Regeneron's EHR-linked genomic and proteomic database, enhancing its drug discovery pipeline and enabling the development of AI-powered digital health solutions. Regeneron will invest up to $200 million in TriNetX as part of this deal, aiming to leverage combined data and AI capabilities to improve disease prediction, prevention, and treatment. The collaboration aligns with Regeneron's mission to build the world's largest human health database and accelerate innovative medicine development.
